Published in Lab Business Week, January 14th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Merck.
Report 1: Merck KGaA and Glenmark Pharmaceuticals S.A, Switzerland, a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL), have entered into an agreement for Glenmark's DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in phase 2 of clinical development.
The transaction is expected to close this year upon approval of the exclusive license to GRC 8200 by the U.S. antitrust agencies under the HSR act.
Under the agreement, Merck KGaA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.